BioMarin Pharmaceutical Inc. ’s Roctavian receives FDA approval

Trial results showed that Roctavian effectively reduced bleeding events for a period of three years following its administration.

Source: bizjournals.com Health Care:Pharmaceuticals headlines - June 30, 2023 Category: Pharmaceuticals Authors: Natalie Wu Source Type: news